192 related articles for article (PubMed ID: 22995320)
21. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
22. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
Choi D; Lee HW; Hur KY; Kim JJ; Park GS; Jang SH; Song YS; Jang KS; Paik SS
World J Gastroenterol; 2009 May; 15(18):2258-64. PubMed ID: 19437567
[TBL] [Abstract][Full Text] [Related]
24. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
25. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
28. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
29. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
30. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
31. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle analysis of the CD133(+) and CD133(-) cells isolated from human colorectal cancer.
Gharagozloo M; Mirzaei HR; Bagherpour B; Rezaei A; Kalantari H; Sanei MH; Hosseini M; Mohajeri G; Tabatabai A; Hashemi M
J Cancer Res Ther; 2012; 8(3):399-403. PubMed ID: 23174722
[TBL] [Abstract][Full Text] [Related]
33. [Experimental investigation of CD133 as a putative marker of tumor-initiating cell in laryngeal carcinoma].
Wei XD; Zhou L; Cheng L; Tian J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Dec; 41(12):940-4. PubMed ID: 17345710
[TBL] [Abstract][Full Text] [Related]
34. CD133 as a target for colon cancer.
Catalano V; Di Franco S; Iovino F; Dieli F; Stassi G; Todaro M
Expert Opin Ther Targets; 2012 Mar; 16(3):259-67. PubMed ID: 22385077
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
36. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of CD133 expression in colorectal cancer: a meta-analysis.
Wang K; Xu J; Zhang J; Huang J
BMC Cancer; 2012 Dec; 12():573. PubMed ID: 23216926
[TBL] [Abstract][Full Text] [Related]
38. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
39. CD133+ human colorectal adenocarcinoma cells are resistant to staining with fluorescent dyes used for analysis of ABC transporter activities.
Gisina AM; Lupatov AY; Karalkin PA; Mainovskaya OA; Petrov LO; Sidorov DV; Frank GA; Yarygin KN
Bull Exp Biol Med; 2014 Nov; 158(1):80-3. PubMed ID: 25403403
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction.
Wu CP; Du HD; Gong HL; Li DW; Tao L; Tian J; Zhou L
Int J Oncol; 2014 May; 44(5):1652-60. PubMed ID: 24573690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
